Print
Advertisement
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
The patient, a 63-year-old male, was diagnosed with HIV-1 infection 31 years before undergoing transplantation.
Advertisement
A meta-analysis of 24 studies observed a decrease in pediatric cancer treatment abandonment after the intervention.
Oral tamibarotene is currently being evaluated in combination with azacitidine and venetoclax in the SELECT-AML-1 trial.
Cilta-cel is now indicated for adult patients who have received at least one prior line of therapy.
Monotherapy with tagraxofusp induced complete remissions in patients with blastic plasmacytoid dendritic cell neoplasm.
Tagraxofusp is the first drug for BPDCN, and the first CD123-targeting drug in oncology, to receive FDA approval.
Palliative care facilitates communication and helps with symptom management, the researchers noted.
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.
Dr. Cavalli was honored for his accomplishments in the fields of leukemia, lymphoma, and breast cancer.
Dr. Witte’s recent research focuses on finding immunological targets for both antibody and cell-mediated therapy.
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
Dr. Shah’s areas of expertise include immunology and immunotherapy, rare tumors, CAR T-cell therapies, and transplantation.
The expansion of the indication was supported by positive data from the KarMMa-3 study.
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.